ECSP982523A - Sal tartrato de un dipeptido sustituido - Google Patents
Sal tartrato de un dipeptido sustituidoInfo
- Publication number
- ECSP982523A ECSP982523A ECSP982523A ECSP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- tartaric acid
- useful
- acid salt
- osteoporosis
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a la sal de ácido (L)-tartárico o de la 2-amino-N-{1-2,4-difluoro-benciloximetil)-2-oxo-2- [3-oxo-3a-piridin -2-ilmetil-2-(2,2,2-trifluoro-etil)-2,3,3aA, 6,7-hexahidro-pirazolo [4,3-c] piridin -5-il] etil}-2-metil-propionamida, la cual es un secretagogo de la hormona de crecimiento endógena. En otro aspecto, esta invención proporciona determinados productos intermedios que son útiles para la síntesis del compuesto anterior. La sal del ácido (L)-tartárico del compuesto de está invención es útil para el tratamiento y/o prevención de la osteoporosis, resistencia a la insulina y otros trastornos o enfermedades asociadas con la diferencia de hormona del crecimiento. La sal del ácido (L)-tartárico del compuesto de la presente invención es también útil para el tratamiento de la osteoporosis cuando se usa en combinación con: un compuesto bisfosfonato, estrógenos, Premarin y opcionalmente progesterona, un agonista o antagonista de estrógenos o calcitonina. Además,la presente invención se refiere a procedimientos que comprenden la administración de un agonista alfa-2-adrenérgico y de la sal del ácido (L)-tartárico del compuesto de esta invención.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP982523 ECSP982523A (es) | 1998-06-08 | 1998-06-08 | Sal tartrato de un dipeptido sustituido |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ECSP982523 ECSP982523A (es) | 1998-06-08 | 1998-06-08 | Sal tartrato de un dipeptido sustituido |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP982523A true ECSP982523A (es) | 1999-01-26 |
Family
ID=42043444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP982523 ECSP982523A (es) | 1998-06-08 | 1998-06-08 | Sal tartrato de un dipeptido sustituido |
Country Status (1)
Country | Link |
---|---|
EC (1) | ECSP982523A (es) |
-
1998
- 1998-06-08 EC ECSP982523 patent/ECSP982523A/es unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4810383A1 (es) | Sal tartrato de un dipeptido sustituido | |
Mohan et al. | Comparison of bone formation responses to parathyroid hormone (1-34),(1-31), and (2-34) in mice | |
US8076316B2 (en) | Steroid compounds and formulations | |
JP4486258B2 (ja) | ヒト副甲状腺ホルモンの改変、調製および使用 | |
JP2632754B2 (ja) | 脳内グルタミン酸遊離抑制剤 | |
Gozes et al. | Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment | |
US7521528B2 (en) | Conformationally constrained parathyroid hormone (PTH) analogs with lactam bridges | |
HU213098B (en) | Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components | |
EP0748817A3 (en) | Parathyroid hormone derivatives and their use | |
US7795220B2 (en) | Conformationally constrained parathyroid hormones with alpha-helix stabilizers | |
US7910544B2 (en) | Conformationally constrained parthyroid hormone (PTH) analogs | |
US7799757B2 (en) | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents | |
BR0100946A (pt) | Metabólitos de hexahidropirazolo[4,3-c] piridina | |
JP2002060348A (ja) | 身体機能低下の治療のための成長ホルモン分泌促進物質の使用 | |
Horiuchi et al. | A multiresponse parathyroid hormone assay: An inhibitor has agonist properties in vivo | |
KLEIN-NULEND et al. | Comparison of the Effects of Synthetic Human Parathyroid Hormone (PTH)-(l–34)-Related Peptide of Malignancy and Bovine PTH-(l–34) on Bone Formation and Resorption in Organ Culture | |
ECSP982523A (es) | Sal tartrato de un dipeptido sustituido | |
KR970004039B1 (ko) | 점막 투여시 흡수 촉진제로서의 시클릭 펩티드 | |
Saggese et al. | Combined treatment with growth hormone and gonadotropin-releasing hormone analogues in children with isolated growth hormone deficiency | |
Escobar et al. | Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome | |
Dresner‐Pollak et al. | Evaluation in vivo of a potent parathyroid hormone antagonist:[Nle8, 18, D‐Trp12, Tyr34] bPTH (7–34) NH2 | |
EP1121113A1 (en) | Methods for regulating bone formation | |
Garcia et al. | Separate binding sites for intact PTH 1-84 and synthetic PTH 1-34 in canine kidney | |
D’Souza | The parathyroid hormone family of ligands and receptors | |
CN110234334B (zh) | 肌肉萎缩抑制组合物 |